Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.


Reference number
Coordinator Annexin Pharmaceuticals AB
Funding from Vinnova SEK 1 800 000
Project duration June 2016 - August 2019
Status Completed

Purpose and goal

The purpose of AnnexVIR-2 is to perform initial in-vitro studies to investigate whether Annexin A5 has the potential to reduce mortality in persons affected by hemorrhagic fevers (e.g. Ebola). The project has also included formulation work and funding related activities. The goal of the project is to obtain sufficient data to enable decisions about more extensive studies on Annexin A5 and hemorrhagic fevers.

Expected results and effects

The obtained results have formed the basis for the Company´s future strategy. The company continues its development work with Annexin A5 as possible pharmaceutical product for hemorrhagic fevers (specifically at Ebola).

Planned approach and implementation

The project has been carried out by Annexin Pharmaceuticals in collaboration with subcontractors who are specialists in manufacturing of biological pharmaceutical products and the execution of safety-classified in-vitro studies. The execution of the project has taken considerably longer time than planned due to an unexpected need for re-formulation. In-vitro studies have been postponed due to unexpected situations in the safety-classified laboratory.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 20 December 2018

Reference number 2016-01351

Page statistics